EGb-761
Pharmaceutical compound
From Wikipedia, the free encyclopedia
EGb-761 (also written EGb 761, branded Gingogink, Tebonin, Tramisal) is a standardised extract of the leaves of the tree Ginkgo biloba, containing flavonoid glycosides and terpene lactones, and used in some countries for symptoms such as cognitive decline, peripheral circulatory disorders, tinnitus and vertigo.[1]
| Clinical data | |
|---|---|
| Trade names | Gingogink; Tebonin; Tramisal |
| Other names | GBE 761; Ginkgo biloba special extract; EGb761 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Not fully established |
| Metabolism | Not fully established |
| Identifiers | |
| CAS Number | |
Mechanism of action
The pharmacological effects of EGb-761 are attributed to multiple mechanisms: antioxidant and free-radical-scavenging actions, modulation of micro-circulation (hemorheological effects), protective effects on mitochondrial function, and possible effects on neuronal signalling and excitotoxicity.[2]
In relation to auditory disorders and tinnitus, it has been proposed that EGb-761 may help stabilize inner-ear microcirculation, reduce oxidative stress, and modulate neuro-auditory pathways.[3]
A systematic review concluded that "there is evidence of efficacy for the standardised extract, EGb 761, ... in the treatment of tinnitus".[4]